Stock Price Quote

GLENMARK PHARMACEUTICALS LTD.

NSE : GLENMARKBSE : 532296ISIN CODE : INE935A01035Industry : Pharmaceuticals & DrugsHouse : Glenmark
BSE957.50-5.5 (-0.57 %)
PREV CLOSE ( ) 963.00
OPEN PRICE ( ) 961.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 21109
TODAY'S LOW / HIGH ( )954.50 968.10
52 WK LOW / HIGH ( )444.3 974.05
NSE958.45-4 (-0.42 %)
PREV CLOSE( ) 962.45
OPEN PRICE ( ) 960.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 958.45 (636)
VOLUME 517943
TODAY'S LOW / HIGH( ) 954.25 968.60
52 WK LOW / HIGH ( )444.3 974
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 18-11 1977
Management Info
Glenn Saldanha - Chairman Glenn Saldanha - Managing Director
Registered Office

Address B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road, ,
Mumbai,
Maharashtra-400026

Phone

Email complianceofficer@glenmarkpharma.com

Website www.glenmarkpharma.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX

NEWS

06Mar Glenmark Pharmaceuticals informs about
Glenmark Pharmaceuticals has informed that it enclosed disclosure pursua..
19Feb Glenmark Pharmaceuticals informs about
Further to letter dated 2nd February, 2024 and pursuant to Regulation 30..
01Feb Infosys, Cochin Shipyard and Glenmark
Infosys has signed a seven-year strategic collaboration with Musgrave, I..
31Jan Glenmark Pharmaceuticals, Jubilant Foo
Glenmark Pharmaceuticals and Ichnos Sciences Inc. (Ichnos), its global f..
31Jan Glenmark Pharmaceuticals partners with
Glenmark Pharmaceuticals (Glenmark) has joined hands with Pfizer to laun..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit-204.08999999999912087.69
Gross Profit -755.019999999999 15718.74
Operating Profit 745.47000000000124587.06
Net Sales 13650.9682206.62

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  26946.00 (0.74%)
M.Cap ( in Cr)57258.37
Sanofi India (BSE)
peergroup  8118.25 (2.06%)
M.Cap ( in Cr)18696.83
Dr. Reddy's Lab (BSE)
peergroup  6155.15 (1.78%)
M.Cap ( in Cr)102679.14
Divi's Lab (BSE)
peergroup  3436.75 (2.14%)
M.Cap ( in Cr)91234.91
Glaxosmithkline Phar (BSE)
peergroup  1943.10 (3.26%)
M.Cap ( in Cr)32917.29

Shareholding Pattern

MUTUAL FUNDS/UTI 8.59%
PROMOTERS 46.65%
NON-INSTITUTION 18.69%
FI/BANKS/INSURANCE 1.88%
GOVERNMENT 0.04%
FII 0%

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. was incorporated in the year 1977. Its today's share price is 957.5. Its current market capitalisation stands at Rs 27019.52 Cr. In the latest quarter, company has reported Gross Sales of Rs. 91817.94 Cr and Total Income of Rs.92066.01 Cr. The company's management includes Harish Kuber, Dipankar Bhattacharjee, Vijayalakshmi Iyer, Saira Ramasastry, DR Mehta, B E Saldanha, Sridhar Gorthi, Rajesh V Desai, Bernard Munos, Brian W Tempest, Cherylann Pinto, VS Mani, Glenn Saldanha, Glenn Saldanha.

It is listed on the BSE with a BSE Code of 532296 , NSE with an NSE Symbol of GLENMARK and ISIN of INE935A01035. It's Registered office is at B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road, Mumbai-400026, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Arthur Andersen & Associates, Price Waterhouse, Suresh Surana & Associates LLP, VK Bahri & Co, Walker Chandiok & Co LLP, Walker, Chandiok & Co, Walker, Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.